Overview

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

Status:
Active, not recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.

Phase:

Phase 3

Details

Lead Sponsor:

Gruppo Oncologico Italiano di Ricerca Clinica

Collaborators:

Bioikos Ambiente Srl
Bristol Myers Squibb Srl Italia
Istituto Toscano Tumori
Mipharm S.p.A.
Temas srl

Treatments:

Antibodies, Monoclonal
Nivolumab